TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06110494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron oxide nanoparticles treatment Ferumoxytol/H2O2
Description: Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl
Description: Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study: NCT02401191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEX60/PE10
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00790374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 2)
Description: 40 mg daily BN83495 for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 3)
Description: 60 mg daily BN83495 for 28 days
Study: NCT06110494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supplementary irrigation
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study: NCT03509298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study: NCT01735916

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CRT-P Implant
Description: The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P Implant
Description: The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care.
Study: NCT03509298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT04006327

Intervention type: OTHER
Intervention: No intervention will be provided as this study is a cross-sectional observational study.
Description: This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
Study: NCT01735916

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CRT-P OFF
Description: Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
Study: NCT04585256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trendelenburg positioning
Description: Women positioned in the trendelenburg position prior to external cephalic version
Study: NCT04031040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio(TM) system therapy
Description: Hypoglossal nerve stimulation system
Study: NCT02225639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 35 mg
Description: Oral 35 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 35 mg
Description: Oral 35 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 55 mg
Description: Oral 55 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 55 mg
Description: Oral 55 mg capsule - active
Study: NCT06464809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping (KT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping (KT)
Study: NCT02324933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Study: NCT02843074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by IV
Study: NCT02324933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Study: NCT04027153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fee based delivery
Description: Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fee based delivery
Description: Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
Study: NCT02843074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Study: NCT00450827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT02933593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
Study: NCT02225639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active
Study: NCT01908075

Intervention type: DRUG
Intervention: FP/SAL

Intervention type: DRUG
Intervention: FP/SAL

Intervention type: DRUG
Intervention: BDP/FOR
Study: NCT01016951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164 Turbuhaler®
Description: Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg.
Study: NCT00450827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody 3F8
Study: NCT00688636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
Study: NCT01016951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Turbuhaler®
Description: Dry powder for inhalation via Turbuhaler, MAD
Study: NCT04195204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Investigators administrated intravenously saline solution as a placebo
Study: NCT03622684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle relaxation according to Jacobson
Study: NCT05031611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intuitive Eating Treatment
Description: Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details.
Study: NCT02124200

Intervention type: DEVICE
Group type: OTHER
Intervention: EGO/CE4, 9mg nicotine
Study: NCT02639624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low bicarbonate dialysate First

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal bicarbonate dialysate First

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal bicarbonate dialysate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low bicarbonate dialysate
Study: NCT03978663

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
Study: NCT03291080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid 13-Cis Retinoic Acid
Description: Liquid 13-Cis Retinoic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extracted capsules 13-CRA
Description: Extracted capsules 13-CRA
Study: NCT02741960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 500 mg metformin three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500 mg placebo three times daily
Study: NCT02935062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Phonological Therapy
Description: Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Software Phonological Therapy- SIFALA
Description: The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Therapy
Description: No intervention to improve speech.
Study: NCT01734681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Study: NCT04541238

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic resonance imaging
Study: NCT04013711

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermography
Description: Thermograms will be acquired of both treated and non-treated cancer site for comparison.
Study: NCT03288662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT and histopathological classification
Description: Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
Study: NCT00566267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg/ezetimibe
Description: see protocol
Study: NCT01612403

Intervention type: DIETARY_SUPPLEMENT
Intervention: zinc sulfate
Description: every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
Study: NCT02596815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median Nerve Neural Mobilization
Description: Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median Nerve Neural Mobilization
Description: Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goniometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Study: NCT00672074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipamorelin
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study: NCT01474681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSC835
Study: NCT03947918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sleep
Description: Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sleep
Description: Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long sleep
Description: Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long sleep
Description: Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
Study: NCT02933593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
Study: NCT04519489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP therapy with telemonitoring
Description: This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.

Intervention type: OTHER
Group type: OTHER
Intervention: AF standard management and OSA general care
Description: Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
Study: NCT02274467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-catheter electric stimulation test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-catheter electric stimulation test
Study: NCT03201471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide + R-CHOP regimen
Description: Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
Study: NCT02330081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol treatment of whole blood
Description: Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood.
Study: NCT00423800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
Description: 1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
Description: 1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks
Study: NCT01572961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicilic acids (Aspirin)
Description: single oral dose of 1g.
Study: NCT00323895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent and balloon angioplasty
Description: CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting stent and balloon angioplasty
Description: CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting stent
Description: CYPHER Select ™ Sirolimus-eluting Stent
Study: NCT01379521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: everolimus placebo
Study: NCT04389983

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium Chain Triglyceride oil
Description: Bulletproof Braine Octane MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium Chain Triglyceride oil
Description: Bulletproof Braine Octane MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium Chain Triglyceride oil
Description: Bulletproof Braine Octane MCT oil
Study: NCT00938041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Tositumomab and Iodine I 131 Tositumomab